Welcome to our dedicated page for Phio Pharmaceuticals SEC filings (Ticker: PHIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding a 300-page biotech filing isn’t easy—especially when Phio Pharmaceuticals’ disclosures dive deep into RNAi chemistry, IND milestones and financing rounds. If you’ve ever searched the 10-K for cash-runway details or hunted through Form 4s to see when executives buy shares ahead of INTASYL trial data, you know the challenge.
Stock Titan solves that problem. Our AI reads every document the moment it hits EDGAR and delivers plain-English answers to the questions investors actually ask: “Phio Pharmaceuticals SEC filings explained simply” and “understanding Phio Pharmaceuticals SEC documents with AI.” Quickly jump from an “Item 1A-Risk Factors” headline to a one-sentence summary, or set real-time alerts for “Phio Pharmaceuticals Form 4 insider transactions real-time.” You’ll also find:
- Complete Phio Pharmaceuticals annual report 10-K simplified—cash burn, R&D spend and INTASYL pipeline updates distilled by AI.
- Every Phio Pharmaceuticals quarterly earnings report 10-Q filing with side-by-side trend charts.
- Immediate access to Phio Pharmaceuticals 8-K material events explained—from trial results to financing announcements.
- Detailed Phio Pharmaceuticals proxy statement executive compensation breakdowns.
The result: faster insight into PH-762 progress, better tracking of Phio Pharmaceuticals insider trading Form 4 transactions, and the context you need to act decisively. Whether you’re scanning Phio Pharmaceuticals earnings report filing analysis or monitoring Phio Pharmaceuticals executive stock transactions Form 4, our platform keeps you ahead of the curve—without wading through biotech jargon.
Phio Pharmaceuticals (PHIO) entered inducement agreements for warrant exercises and issued new warrants. Holders agreed to exercise 5,663,182 existing warrants, with portions exercised at $2.00 and $2.485, and 4,654,586 exercised or to be exercised at a reduced $2.05. In return, Phio issued unregistered Series A Warrants for up to 11,326,364 shares at $2.05, exercisable immediately for 24 months from the resale registration’s effective date.
Initial closings on November 4 and 6 generated approximately $12.6 million in gross proceeds, tied to 5,313,182 exercises and 10,626,364 new warrants issued. Additional closings are expected by November 18 for 350,000 more exercises and 700,000 additional new warrants. Phio expects total gross proceeds of about $13.4 million before fees and expenses, including $1,415,795.50 paid for the new warrants. The company will file a resale registration statement for the new warrant shares within 20 days and agreed to a brief issuance blackout. H.C. Wainwright serves as placement agent with cash fees and warrants as compensation.
Phio Pharmaceuticals (PHIO) reported early clinical signals in its Phase 1b dose‑escalation trial of INTASYL PH‑762 for cutaneous squamous cell carcinoma. The company announced Day 36 outcomes in the fifth and final dose cohort: 100% tumor clearance (Complete Response) in one patient, greater than 90% (Near Complete Response) in a second, and greater than 50% (Partial Response) in a third.
Phio also stated that the Safety Monitoring Committee issued a favorable review of safety data at the maximum dose. These updates come from the ongoing Phase 1b dose escalation study (NCT 06014086).
Phio Pharmaceuticals (PHIO) filed an 8-K announcing board changes. On October 31, 2025, Robert Ferrara resigned from the Board, the Compensation and Audit Committees, and as Lead Independent Director, effective immediately. The company states his decision to resign was not the result of any disagreement with the company.
Pursuant to the Governance Committee’s recommendation and following the resignation, the Board reduced its size from six to five members, leaving no vacancies. The company also announced the appointment of David Deming as Lead Independent Director in a press release issued on October 31, 2025, which is furnished as Exhibit 99.1.
Phio Pharmaceuticals (PHIO) amended an insider filing to report a corrected grant of restricted stock units. Director Robert L. Ferrara was granted 23,100 restricted stock units on 09/11/2025 that will convert into common shares when they vest on the first annual anniversary of the grant. Following this grant and existing unvested RSUs, Ferrara beneficially owns 38,766 shares of common stock; the amended filing corrects previously reported counts that understated the grant and total ownership. The amendment also notes that reported share counts were adjusted for prior reverse stock splits.
David H. Deming, a director of Phio Pharmaceuticals Corp. (PHIO), reported an acquisition on 09/11/2025 of 14,000 shares of common stock through restricted stock units (RSUs) with a reported price of $0. The filing states these shares represent units that will vest on the first annual anniversary of the grant and that the 14,000 shares reported include common stock underlying unvested RSUs.
The Form 4 was signed by attorney-in-fact Lisa C. Carson on 09/15/2025. The transaction increases the director’s beneficial ownership by the 14,000 shares subject to future vesting; no cash purchase price was reported in the filing.
Phio Pharmaceuticals (PHIO) director Curtis Lockshin reported an insider grant and updated holdings on Form 4. On 09/11/2025 he was granted 16,200 shares (reported as shares underlying a restricted stock unit) that will vest on the first annual anniversary of the grant; the grant was recorded at a $0 price. After the reported transaction, the filing shows Mr. Lockshin beneficially owns 18,555 shares, which includes shares underlying unvested restricted stock units. The filing notes the reported totals were adjusted for prior reverse stock splits and the Form 4 was signed on 09/15/2025 by an attorney-in-fact.
Phio Pharmaceuticals insider Jonathan E. Freeman reported acquisition of 14,700 shares of common stock on 09/11/2025 through restricted stock units that will vest on the first annual anniversary of the grant. Following the reported transaction Freeman beneficially owns 16,055 shares, a figure that includes other unvested restricted stock units. The filing states the reported amounts were adjusted to reflect prior reverse stock splits. The form was signed by an attorney-in-fact on behalf of the reporting person.
Robert L. Ferrara, a director of Phio Pharmaceuticals Corp. (PHIO), reported acquisition of 23,000 shares of common stock represented by restricted stock units on 09/11/2025. The RSUs vest on the first annual anniversary of the grant and the reported beneficial ownership following the transaction is 38,666 shares, which includes shares underlying unvested RSUs. The filing notes the reported share totals were adjusted for prior reverse stock splits. The disclosure was submitted on a Form 4 by a single reporting person and includes a power of attorney exhibit.
Phio Pharmaceuticals (PHIO) reporting person Lisa C. Carson, who is listed as a director and VP, Finance and Administration, reported a non-derivative acquisition on 09/11/2025. The filing shows 47,000 shares of common stock were acquired at $0, representing shares underlying a restricted stock unit grant. The filing states those shares "will vest on the first annual anniversary of the grant," and that the 47,000 shares reported include common stock underlying unvested restricted stock units. The form is signed 09/15/2025.
FAQ
What is the current stock price of Phio Pharmaceuticals (PHIO)?
What is the market cap of Phio Pharmaceuticals (PHIO)?
